Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Renata Cífková et al.|New England Journal of Medicine|2017Cited by 9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Jean MacFadyen et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Dimitri P. Mikhailidis, Manfredi Rizzo et al.|Archives of Medical Science|2015Cited by 383
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert PanelArrigo F.G. Cicero, Maciej Banach, Alessandro Colletti et al.|Archives of Medical Science|2017Cited by 288